Long Covid sufferers have experienced a wider set of symptoms than previously thought including hair loss and sexual dysfunction, new research has found.
A study published in Nature Medicine today (25th July 2022) found that patients with a primary care record of infection with the virus that causes Covid-19 (SARS-CoV-2 coronavirus) reported 62 symptoms much more frequently 12 weeks after initial infection than those who hadn’t contracted the virus.
Anonymised electronic health records of 2.4 million people in the UK were analysed by researchers from the University of Birmingham alongside a team of clinicians and researchers across England, and was funded by the National Institute for Health and Care Research and UK Research and Innovation. The data taken between January 2020 and April 2021 comprised of 486,149 people with prior infection, and 1.9 million people with no indication of coronavirus infection after matching for other clinical diagnoses.
Using only non-hospitalised patients, the team of researchers were able to identify three categories of distinct symptoms reported by people with persistent health problems after infection.
Patterns of symptoms tended to be grouped into respiratory symptoms, mental health and cognitive problems, and then a broader range of symptoms. While the most common symptoms include anosmia (loss of sense of smell), shortness of breath, chest pain and fever; others include:
- apraxia (inability to perform familiar movements or commands),
- bowel incontinence,
- erectile dysfunction,
- limb swelling
Dr Shamil Haroon, Associate Clinical Professor in Public Health at the University of Birmingham is the senior author on the study. Dr Haroon said:
“This research validates what patients have been telling clinicians and policy makers throughout the pandemic, that the symptoms of Long Covid are extremely broad and cannot be fully accounted for by other factors such as lifestyle risk factors or chronic health conditions.”
“The symptoms we identified should help clinicians and clinical guideline developers to improve the assessment of patients with long-term effects from Covid-19, and to subsequently consider how this symptom burden can be best managed.”
Patient partner and co-author of this study Jennifer Camaradou said:
“This study is instrumental in creating and adding further value to understanding the complexity and pathology of long COVID. It highlights the degree and diversity of expression of symptoms between different clusters. Patients with pre-existing health conditions will also welcome the additional analysis on risk factors.”
Several other patient partners involved in the therapies for long COVID (TLC) study have expressed their views on living with long COVID, accessible at:
As well as identifying a wider set of symptoms, the research team also found key demographic groups and behaviours which put people at increased risk of developing Long Covid.
The study suggests that females, younger people; or belonging to a black, mixed or other ethnic group are at greater risk of developing Long Covid. In addition, people from low socioeconomic backgrounds, smokers, people who are overweight or obese, as well as the presence of a wide range of health conditions were associated with reporting persistent symptoms.
Anuradhaa Subramanian, Research Fellow at the Institute of Applied Health Research, University of Birmingham and lead author of the paper said:
“Our data analyses of risk factors are of particular interest because it helps us to consider what could potentially be causing or contributing to Long Covid. We already know that certain modifiable traits such as smoking and obesity put people at increased risk of various diseases and conditions, including Long Covid. However, others such as biological sex and ethnicity also appear to be important.
“Women are for example more likely to experience autoimmune diseases. Seeing the increased likelihood of women having Long Covid in our study increases our interest in investigating whether autoimmunity or other causes may explain the increased risk in women. These observations will help to further narrow the focus on factors to investigate that may be causing these persistent symptoms after an infection, and how we can help patients who are experiencing them.”
Patient records for 2.3m people enabled the research team to capture post SARS-CoV-2 infections at a unique point in the global pandemic. The study focuses on the first phase of the pandemic in the UK between January 2020 and April 2021 and provided the team with an opportunity to compare meaningful numbers of people who had coronavirus infections alongside a control group of uninfected people.
The interdisciplinary team involved epidemiologists, clinicians, data scientists, statisticians, and patients to decode electronic health records to accurately capture persistent symptoms experienced after infection.
Dr Shamil Haroon said:
“The results are both a testament to the opportunities that these public health datasets provide, and to the power of collaborative work to provide much needed evidence around the experiences of many people who have been affected by persistent symptoms after infection with the coronavirus. I hope our research will also further validate the voices of patients and involvement groups and provide an approach to support healthcare responses to new and emerging diseases.”
For media enquiries please contact Tim Mayo, Press Office, University of Birmingham, tel: +44 (0)7920 405040: email: email@example.com
Notes to Editor:
About the University of Birmingham
- The University of Birmingham is ranked amongst the world’s top 100 institutions. Its work brings people from across the world to Birmingham, including researchers, teachers and more than 6,500 international students from over 150 countries.
- The University of Birmingham is a member of Birmingham Health Partners (BHP), a strategic alliance which transcends organisational boundaries to rapidly translate healthcare research findings into new diagnostics, drugs and devices for patients. Birmingham Health Partners is a strategic alliance between five organisations who collaborate to bring healthcare innovations through to clinical application:
- University of Birmingham
- University Hospitals Birmingham NHS Foundation Trust
- Birmingham Women's and Children's Hospitals NHS Foundation Trust
- Sandwell and West Birmingham Hospitals NHS Trust
- West Midlands Academic Health Science Network
About UK Research and Innovation
- UK Research and Innovation (UKRI) is the UK’s largest public funder of research and innovation and is composed of seven disciplinary research councils, Innovate UK and Research England. Annually, we invest more than £8 billion to advance our understanding of people and the world around us and deliver benefits for society, the economy and the environment. Working in partnership, we aim to shape a more connected and agile research and innovation system in the UK that is an integral part of society, giving everyone the opportunity to participate and to benefit. Find out more in our new 5-year strategy, Transforming Tomorrow Together.
About the Medicines and Healthcare products Regulatory Agency
- The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines, medical devices and blood components for transfusion in the UK. gov.uk/mhra
- CPRD data services, from the MHRA, provide the life sciences sector with anonymised primary care (NHS) datasets that can be linked to other datasets. Researchers can access and use different combinations of these datasets to develop and run clinical projects and to deliver research outputs that can help to improve and safeguard public health. cprd.com
- This study was conducted using CPRD data services from the MHRA.
Method of Research
Subject of Research
Symptoms and risk factors for long COVID in non-hospitalized adults
Article Publication Date